European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer

On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer resistant to or progressive after an oxaliplati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Stanel, Stefan Cristian, Sjöberg, Jan, Salmonson, Tomas, Foggi, Paolo, Caleno, Mariapaola, Melchiorri, Daniela, Gravanis, Iordanis, Tzogani, Kyriaki, Pignatti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: ESMO Open 2017
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519808/
https://ncbi.nlm.nih.gov/pubmed/28761750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000190
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados